← Back

Withdrawal Notice

This paper was originally published in Aging Advance Online Publications on June 27, 2021.

In compliance with Aging's withdrawal policy, the paper was withdrawn in its entirety. It will not appear in Aging internal or any external indexes or archives.

WITHDRAWN: Local anesthetic levobupivacaine induces ferroptosis and inhibits progression by up-regulating p53 in non-small cell lung cancer

class="figure-viewer-img"

Figure 5. Levobupivacaine induces ferroptosis by regulating p53 in NSCLC cells. (A) The A549 and A427 cells were treated with p53 shRNA. The expression of p53 was measured by qPCR in the cells (B and C) The A549 and A427 cells were co-treated with 5 mmol/L erastin and 2 mM levobupivacaine, or co-treated with 5 mmol/L erastin, 2 mM levobupivacaine and p53 shRNA. The cell growth was analyzed by MTT assays. (D–J) The A549 and A427 cells were treated with levobupivacaine (2 mM) or co-treated with 2 mM levobupivacaine and p53 shRNA. (D and E) The levels of ROS were measure by flow cytometry analysis in the cells. (F–I) The levels of iron and Fe2+ were analyzed by Iron Assay Kit. (J) The expression of GPX4, SLC7A11, and β-actin was measured by Western blot analysis in the cells. Data are presented as mean ± SD. Statistic significant differences were indicated: *P < 0.01.